SynthesisDrug and alcohol dependence2007
Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis.
Synthesis in Drug and alcohol dependence, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts.Behavior genetics · 2016Pooled it
- Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1.Biological psychiatry · 2015Pooled it
- Allele frequency and genotype distribution of the opioid receptor μ-1 (OPRM1) A118G polymorphism in the Western Saudi population.Journal of applied biomedicine · 2023Article
- Mu opioid receptor gene variant modulates subjective response to smoked cannabis.American journal of translational research · 2022Article
- Naltrexone Use in Treating Hypersexuality Induced by Dopamine Replacement Therapy: Impact ofInternational journal of molecular sciences · 2020Review
- Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism.Current oncology reports · 2020Review
- An integrative analysis of genome-wide association study and regulatory SNP annotation datasets identified candidate genes for bipolar disorder.International journal of bipolar disorders · 2020Article
- Genome-Wide Association Study of Opioid Cessation.Journal of clinical medicine · 2020Article
- A review of opioid addiction genetics.Current opinion in psychology · 2019Review
- An update on the safety of prescribing opioids in pediatrics.Expert opinion on drug safety · 2019Review
- Pharmacogenetics of OPRM1.Pharmacology, biochemistry, and behavior · 2014Review
- Mu opioid receptor gene: new point mutations in opioid addicts.Basic and clinical neuroscience · 2014Article
- Association of OPRD1 polymorphisms with heroin dependence in a large case-control series.Addiction biology · 2014Article
- Low frequency genetic variants in the μ-opioid receptor (OPRM1) affect risk for addiction to heroin and cocaine.Neuroscience letters · 2013Article
- Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside?Journal of pain research · 2013Article
- Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.The Journal of clinical investigation · 2012Review
- The genetics of addiction-a translational perspective.Translational psychiatry · 2012Review
- Common and specific liability to addiction: approaches to association studies of opioid addiction.Drug and alcohol dependence · 2012Review
- The genetics of the opioid system and specific drug addictions.Human genetics · 2012Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
OPRM1, which codes for the mu-opioid receptor, is the most frequently studied candidate gene for opioid dependence. Despite numerous allelic association studies, no definitive conclusion has been reached regarding the role of OPRM1 polymorphisms in determining risk for opioid dependence. We attempted to resolve this by conducting a family-based association study and meta-analysis which may be more robust and powerful, respectively, than traditional case-control analyses. First, we genotyped three single nucleotide polymorphisms (SNPs) of OPRM1 in 1208 individuals from 473 Han Chinese families ascertained on the basis of having two or more siblings with DSM-IV-defined opioid dependence. The Val6Ala and Arg111His SNPs were detected, but with low minor allele frequencies (0.002 and 0.001, respectively). The Asn40Asp SNP was more informative (minor allele frequency: 0.419), but no significant evidence was observed for either a dominant (p=0.810) or additive (p=0.406) effect of this polymorphism on risk for opioid dependence. In addition, a meta-analysis of case-control studies of opioid dependence was performed, and found a similar lack of evidence for an association with the Asn40Asp SNP (p=0.859). Although a role of OPRM1 polymorphisms in determining risk for opioid dependence cannot be entirely discounted, a major contribution of the Asn40Asp polymorphism seems unlikely. Further analysis is warranted in samples from specific ancestral groups. In addition, it is critical that other OPRM1 variants, including all haplotype-tagging and amino-acid-coding SNPs, be tested for an influence on risk for opioid dependence, since the Asn40Asp polymorphism is only one of several hundred known mutations in the gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.